SLC16A12 Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-59530
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptides corresponding to SLC16A12(solute carrier family 16, member 12 (monocarboxylic acid transporter 12)) The peptide sequence was selected from the N terminal of SLC16A12.
Peptide sequence WMIVAGCFLVTICTRAVTRCISIFFVEFQTYFTQDYAQTAWIHSIVDCVT The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for SLC16A12 Antibody - BSA Free
Western Blot: SLC16A12 Antibody [NBP1-59530]
Western Blot: SLC16A12 Antibody [NBP1-59530] - Jurkat cell lysate, concentration 0.2-1 ug/ml.Applications for SLC16A12 Antibody - BSA Free
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: SLC16A12
Long Name
Solute Carrier Family 16 Member 12
Alternate Names
CJMG, MCT12
Gene Symbol
SLC16A12
UniProt
Additional SLC16A12 Products
Product Documents for SLC16A12 Antibody - BSA Free
Product Specific Notices for SLC16A12 Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...